These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

364 related items for PubMed ID: 25965880

  • 1. CBL controls a tyrosine kinase network involving AXL, SYK and LYN in nilotinib-resistant chronic myeloid leukaemia.
    Gioia R, Trégoat C, Dumas PY, Lagarde V, Prouzet-Mauléon V, Desplat V, Sirvent A, Praloran V, Lippert E, Villacreces A, Leconet W, Robert B, Vigon I, Roche S, Mahon FX, Pasquet JM.
    J Pathol; 2015 Sep; 237(1):14-24. PubMed ID: 25965880
    [Abstract] [Full Text] [Related]

  • 2. Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells.
    Gioia R, Leroy C, Drullion C, Lagarde V, Etienne G, Dulucq S, Lippert E, Roche S, Mahon FX, Pasquet JM.
    Blood; 2011 Aug 25; 118(8):2211-21. PubMed ID: 21730355
    [Abstract] [Full Text] [Related]

  • 3. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells.
    Wu J, Meng F, Lu H, Kong L, Bornmann W, Peng Z, Talpaz M, Donato NJ.
    Blood; 2008 Apr 01; 111(7):3821-9. PubMed ID: 18235045
    [Abstract] [Full Text] [Related]

  • 4. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression.
    Mahon FX, Hayette S, Lagarde V, Belloc F, Turcq B, Nicolini F, Belanger C, Manley PW, Leroy C, Etienne G, Roche S, Pasquet JM.
    Cancer Res; 2008 Dec 01; 68(23):9809-16. PubMed ID: 19047160
    [Abstract] [Full Text] [Related]

  • 5. A novel co-operative mechanism linking TGFβ and Lyn kinase activation to imatinib resistance in chronic myeloid leukaemia cells.
    Smith PG, Tanaka H, Chantry A.
    Oncotarget; 2012 May 01; 3(5):518-24. PubMed ID: 22643838
    [Abstract] [Full Text] [Related]

  • 6. Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells.
    Pénzes K, Baumann C, Szabadkai I, Orfi L, Kéri G, Ullrich A, Torka R.
    Cancer Biol Ther; 2014 May 01; 15(11):1571-82. PubMed ID: 25482942
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of imatinib-mediated apoptosis by the caspase-cleaved form of the tyrosine kinase Lyn in chronic myelogenous leukemia cells.
    Gamas P, Marchetti S, Puissant A, Grosso S, Jacquel A, Colosetti P, Pasquet JM, Mahon FX, Cassuto JP, Auberger P.
    Leukemia; 2009 Aug 01; 23(8):1500-6. PubMed ID: 19340007
    [Abstract] [Full Text] [Related]

  • 8. Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia.
    Ben-Batalla I, Erdmann R, Jørgensen H, Mitchell R, Ernst T, von Amsberg G, Schafhausen P, Velthaus JL, Rankin S, Clark RE, Koschmieder S, Schultze A, Mitra S, Vandenberghe P, Brümmendorf TH, Carmeliet P, Hochhaus A, Pantel K, Bokemeyer C, Helgason GV, Holyoake TL, Loges S.
    Clin Cancer Res; 2017 May 01; 23(9):2289-2300. PubMed ID: 27856601
    [Abstract] [Full Text] [Related]

  • 9. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C, Bianchini M, Bengió R, Larripa I.
    Blood Cells Mol Dis; 2014 May 01; 52(2-3):121-5. PubMed ID: 24091144
    [Abstract] [Full Text] [Related]

  • 10. Dasatinib preferentially induces apoptosis by inhibiting Lyn kinase in nilotinib-resistant chronic myeloid leukemia cell line.
    Okabe S, Tauchi T, Tanaka Y, Ohyashiki K.
    J Hematol Oncol; 2011 Aug 02; 4(1):32. PubMed ID: 21806844
    [Abstract] [Full Text] [Related]

  • 11. Gas6/AXL Signaling Regulates Self-Renewal of Chronic Myelogenous Leukemia Stem Cells by Stabilizing β-Catenin.
    Jin Y, Nie D, Li J, Du X, Lu Y, Li Y, Liu C, Zhou J, Pan J.
    Clin Cancer Res; 2017 Jun 01; 23(11):2842-2855. PubMed ID: 27852702
    [Abstract] [Full Text] [Related]

  • 12. Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells.
    Dufies M, Jacquel A, Belhacene N, Robert G, Cluzeau T, Luciano F, Cassuto JP, Raynaud S, Auberger P.
    Oncotarget; 2011 Nov 01; 2(11):874-85. PubMed ID: 22141136
    [Abstract] [Full Text] [Related]

  • 13. Cbl-mediated degradation of Lyn and Fyn induced by constitutive fibroblast growth factor receptor-2 activation supports osteoblast differentiation.
    Kaabeche K, Lemonnier J, Le Mée S, Caverzasio J, Marie PJ.
    J Biol Chem; 2004 Aug 27; 279(35):36259-67. PubMed ID: 15190072
    [Abstract] [Full Text] [Related]

  • 14. Inverse regulation of bridging integrator 1 and BCR-ABL1 in chronic myeloid leukemia.
    Trino S, De Luca L, Simeon V, Laurenzana I, Morano A, Caivano A, La Rocca F, Pietrantuono G, Bianchino G, Grieco V, Signorino E, Fragasso A, Bochicchio MT, Venturi C, Rosti G, Martinelli G, Del Vecchio L, Cilloni D, Musto P.
    Tumour Biol; 2016 Jan 27; 37(1):217-25. PubMed ID: 26194865
    [Abstract] [Full Text] [Related]

  • 15. Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification.
    Morinaga K, Yamauchi T, Kimura S, Maekawa T, Ueda T.
    Int J Cancer; 2008 Jun 01; 122(11):2621-7. PubMed ID: 18338755
    [Abstract] [Full Text] [Related]

  • 16. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.
    Wu J, Meng F, Kong LY, Peng Z, Ying Y, Bornmann WG, Darnay BG, Lamothe B, Sun H, Talpaz M, Donato NJ.
    J Natl Cancer Inst; 2008 Jul 02; 100(13):926-39. PubMed ID: 18577747
    [Abstract] [Full Text] [Related]

  • 17. Hematopoietic progenitor kinase 1 down-regulates the oncogenic receptor tyrosine kinase AXL in pancreatic cancer.
    Song X, Akasaka H, Wang H, Abbasgholizadeh R, Shin JH, Zang F, Chen J, Logsdon CD, Maitra A, Bean AJ, Wang H.
    J Biol Chem; 2020 Feb 21; 295(8):2348-2358. PubMed ID: 31959629
    [Abstract] [Full Text] [Related]

  • 18. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
    Nimmanapalli R, O'Bryan E, Huang M, Bali P, Burnette PK, Loughran T, Tepperberg J, Jove R, Bhalla K.
    Cancer Res; 2002 Oct 15; 62(20):5761-9. PubMed ID: 12384536
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of ponatinib against ABL tyrosine kinase inhibitor-resistant leukemia cells.
    Okabe S, Tauchi T, Tanaka Y, Ohyashiki K.
    Biochem Biophys Res Commun; 2013 Jun 07; 435(3):506-11. PubMed ID: 23684619
    [Abstract] [Full Text] [Related]

  • 20. Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival.
    Ammoun S, Provenzano L, Zhou L, Barczyk M, Evans K, Hilton DA, Hafizi S, Hanemann CO.
    Oncogene; 2014 Jan 16; 33(3):336-46. PubMed ID: 23318455
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.